In preclinical studies, dual-variable domain immunoglobulin targeting simultaneously DLL4 and VEGF (ABT-165, dilpacimab), significantly inhibited tumor growth and decreased functional tumor angiogenesis in U87-MG human GBM xenograft model [222]. This evidence concerns the gene DLL4 and glioblastoma.